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A B S T R A C T
Quantitative techniques improve our understanding of tumor volume data for combination treatments and its
translation across in vivo models and species. The focus of this paper is therefore on understanding in vivo data,
highlighting key structural elements of pharmacodynamic tumor models, and challenging these methods from a
translational point of view. We introduce the concept of Tumor Static Exposure (TSE) both for single and
multiple combined anticancer agents. The TSE curve separates all possible exposure combinations into regions of
tumor growth and tumor shrinkage. Moreover, the degree of curvature of the TSE curve indicates the degree of
synergy or antagonism. We demonstrate the TSE approach by two case studies. The ﬁrst examines a combination
of the drugs cetuximab and cisplatin. The TSE curve associated with this combination reveals a weak synergistic
eﬀect, suggesting only modest gains from combination therapy. The second case study examines combinations of
ionizing radiation and a radiosensitizing agent. In this case, the TSE curve exhibits a pronounced curvature,
indicating a strong synergistic eﬀect; tumor regression can be achieved at signiﬁcantly lower exposure levels
and/or radiation doses. Finally, an allometric approach to human dose prediction demonstrates the translational
power of the model and the TSE concept. We conclude that the TSE approach, which embodies model-based
measures of both drug (potency) and target properties (tumor growth rate), has a strong potential for ranking of
compounds, supporting compound selection, and translating preclinical ﬁndings to humans.
1. Introduction
Pharmacodynamic models are commonly used to aid decision-
making in drug discovery and development. In oncology, tumor growth
inhibition models have been used extensively in the past decades (Evans
et al., 2014; Ribba et al., 2014; Simeoni et al., 2004; Tate et al., 2014).
For a recent review, see Mould et al. (2015). Some growth models are
empirical (Simeoni et al., 2004), whereas others have a more me-
chanistic foundation (Jumbe et al., 2010; Wendling et al., 2016). After
being calibrated to experimental data, the models are used to evaluate,
predict, and guide future experimental designs (Hutchinson et al.,
2016). Models are also used in translational eﬀorts to predict ﬁrst-in-
man doses, using techniques such as allometric scaling (Boxenbaum,
1982, 1984).
Tumor growth inhibition models also exist for combination thera-
pies (Goteti et al., 2010; Rocchetti et al., 2013), with the objective of
evaluating and comparing diﬀerent dose combinations with respect to
eﬃcacy and drug synergies. Many techniques have been proposed to
evaluate drug interactions (Foucquier and Guedj, 2015). Of these,
perhaps the most commonly used approach is the isobologram, which
plots iso-eﬀective dose combinations and determines synergy or an-
tagonism based on the shape of the resulting curve (Grabovsky and
Tallarida, 2004; Tallarida, 2006). Until recently, no isobologram-like
techniques had been explored for diﬀerent exposure-based models, in-
cluding tumor models. Moreover, tumor models and techniques have
been studied primarily for chemical interventions, thereby excluding an
important pillar of modern oncology treatment – radiation therapy
(Baskar et al., 2012).
This paper focuses on two questions: Can quantitative techniques
provide a better understanding of tumor volume data when combinations of
chemicals and radiation are used? and What translational potential does
such an approach have? Our aim is to chisel out relevant model struc-
tures that enhance both the underlying mechanisms of action and the
predictive power of the model. The methodology is demonstrated by in
vivo data from two previous studies (Cardilin et al., 2017, 2018). Case
study I introduces the Tumor Static Concentration (TSC) for both a
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single compound and multiple compounds given in combination. The
analysis focuses speciﬁcally on deriving useful quantitative tools and
then implementing graphical ways to view additivity, synergy or an-
tagonism based on exposure metrics. Case study II expands the methods
to also include radiation therapy as a co-variate. The combination of
drug concentrations and radiation is then called Tumor Static Exposure
(TSE). Case study II examines combination therapy with ionizing ra-
diation and a radiosensitizing agent that exhibit a substantial level of
synergy, manifesting as a more pronounced curvature of the TSE curve.
We also thoroughly describe the two semi-mechanistic tumor models
used to describe the experimental data in the case studies. Finally, we
discuss how TSE can be used in translational eﬀorts, be implemented
into the drug discovery process, and for communication with a biolo-
gically-oriented audience.
2. Background
The concept of a threshold concentration has been applied to var-
ious tumor models and for diﬀerent anti-cancer agents (Jumbe et al.,
2010; Magni et al., 2006; Simeoni et al., 2004). Jumbe et al. (2010)
derived the TSC for a single compound. Koch et al. (2009) derived an
equation for threshold concentrations for a combination of two com-
pounds. Later, the TSC curve was introduced as a graphical tool con-
trasting the isobologram (Cardilin et al., 2017; Gabrielsson et al., 2016).
In particular, Cardilin et al. (2017) discussed how the shape of the TSC
curve was associated with the combined eﬀect (synergy or antagonism)
of the combination treatment. Moreover, a TSC-like curve was also
proposed by Miao et al. (2016) and for more general combination eﬀect
terms by Koch et al. (2016) under the name half maximal-eﬀect curve.
Most recently, Cardilin et al. (2016, 2018) extended the TSC concept to
combinations involving ionizing radiation by introducing the Tumor
Static Exposure (TSE) curve. In this section, we provide a brief intuitive
description of the TSE concept. We refer to Appendix A for a more
technical treatment of the subject.
The tumor is exposed to a single compound A during monotherapy
(Fig. 1a), where CA denotes the plasma concentration of drug. If the
drug is suﬃciently potent, at some concentrations maintained over an
extended period of time, the tumor will start to shrink. At concentra-
tions below the TSC, which are insuﬃcient for tumor regression, the
drug will at best slow down the tumor growth. In particular, there will
also be a value ofCA in between that will keep the tumor in stasis, which
we call the TSC value (Fig. 1a). In the case of radiation therapy, or when
plasma concentrations cannot be measured, we may prefer to use the
dose. For example, we may deﬁne a Tumor Static Dose to be the
minimum daily radiation dose that will keep the tumor in stasis. This
will lead to diﬀerent values depending on administration schedule. In
order to cover both cases we generally refer to the concept as Tumor
Static Exposure (TSE).
The TSE concept can be generalized to the case where two com-
pounds are given simultaneously as combination therapy. Let A and B
denote the compounds and let CA, and CB be their plasma concentra-
tions. For each ﬁxed value of CA, we may ﬁnd a value of CB such that
maintained simultaneous exposure to both compounds leads to tumor
stasis. Hence, we obtain a collection of concentration pairs (CA, CB) that
all lead to tumor stasis. These pairs form a curve in the plane formed
with CA along the x-axis and CB along the y-axis (Fig. 1b). We refer to
this curve as the TSE curve for the compounds A and B. Note that this
curve separates regions of concentration pairs corresponding to tumor
growth (red) and tumor shrinkage (green).
This procedure can be extended to combinations involving three or
more compounds, leading to a hypersurface in higher-dimensional
concentration space. The scenario with three compounds A, B, and C
with plasma concentrations CA along the x-axis, CB along the y-axis, and
CC along the z-axis is illustrated in Fig. 1c.
3. Case study I: cetuximab and cisplatin
3.1. Problem formulation
This case study is based on results that were reported in a previous
publication (Cardilin et al., 2017). Cetuximab is an epidermal growth
factor receptor (EGFR) inhibitor used clinically to treat certain color-
ectal and head-and-neck cancers, either as monotherapy or as combi-
nation therapy together with, e.g., irinotecan, cisplatin and other pla-
tinum-based chemotherapy, or radiation (Bou-Assaly and Mukherji,
2010; Reynolds and Wagstaﬀ, 2004). This in vivo study was aimed at
investigating combination therapy with cetuximab and cisplatin to treat
non-small cell lung cancer (NSCLC). Our goal was to develop a tumor
model to describe the experimental data and use the model for eva-
luation with respect to synergy and overall eﬃcacy using TSE curves.
3.2. Experimental data
Forty patient-derived xenograft (PDx) models in female mice were
used in the study. The animals were divided into four treatment arms
with =N 10 animals in each of the following arms: (A) vehicle, (B)
cetuximab monotherapy (30 mg/kg per dose), (C) cisplatin mono-
therapy (5mg/kg per dose), and (D) combination therapy with cetux-
imab (30mg/kg per dose) and cisplatin (5 mg/kg per dose). The mice
were given doses twice a week for two weeks. Tumor length (L) and
width (W ) were measured twice a week for 28 days. Tumor volumes
were estimated using the formula: = ×V L W /22 . The details of this
Fig. 1. a) TSE value of an anti-cancer agent (black). Exposure lower than the TSE value (red) results in tumor growth, whereas exposure greater than the TSE value
(green) results in tumor shrinkage. b) TSE curve for combinations of two anti-cancer agents with concentrations C1 andC2. Exposure pairs below the curve (red) yield
tumor regression, whereas exposure pairs above the curve (green) yields tumor shrinkage. c) TSE surface for combinations of three anti-cancer agents with con-
centrations C1, C2, and C3. Exposure triples below the TSE surface (red) result in tumor growth, whereas exposure triples above the curve (green) result in tumor
regression. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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study were reported previously (Amendt et al., 2014; Cardilin et al.,
2017). Experimental and model-predicted time courses for each of the
four treatment arms are shown in Fig. 2.
3.3. Pharmacodynamic model analysis
Standard one- and two-compartment pharmacokinetic models were
used to describe plasma exposure of cetuximab and cisplatin, respec-
tively. The models, as well as the parameter estimates, were taken from
the literature. Further details can be found in Cardilin et al. (2017).
A pharmacodynamic tumor model was developed to describe tumor
evolution over time. The model consists of a main compartment of
proliferating cells, and a set of damage compartments that each dying
cell must traverse before disappearing. The drug action of cetuximab is
described as an inhibition of the proliferation rate according to an in-
hibitory Emax-function ( =I 1max ), whereas the drug action of cisplatin is
described as a linear stimulation of the natural death rate (Fig. 3).
The pharmacodynamic model is deﬁned by the following system of
diﬀerential equations
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− +
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= −
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= + + +
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where V1 is the main compartment and V V, ,2 3 and V4 are the damage
compartments, Vtotal is the total tumor volume, kg and kk are the growth
and kill rates, IC50 is the concentration of cetuximab needed to achieve
50% inhibition of the proliferation, and b is a pharmacodynamic
parameter associated with cisplatin. The initial conditions for each
tumor volume compartment are given by
= =−V k
k
V i(0) ( ) , 1, 2, 3, 4i k
g
i 1 0
(10)
whereV 0 is the initial volume of the main compartment. The parameter
estimates for the TGI model were, as reported in the original article,
= −k 0.0060 hg 1, = −k 0.0039 hk 1, =IC 994 μg/mL50 , =b 0.0093 mL/ng,
and =V 60 mm0 3.
3.4. Tumor static exposure for cetuximab and cisplatin
For the model in Eq. (9), an expression for the TSE curve can be
found using the following reasoning: The main compartment, V1, is the
only compartment where cells proliferate. Hence, if V1 is eradicated the
entire tumor will eventually be eradicated as well. Therefore, if dV1/
dt< 0 the tumor will eventually be eradicated. SinceV1 will not be zero
unless the tumor is already eradicated, this implies that Eq. (11) must
hold.
⎜ ⎟⎛⎝ − +
⎞
⎠ − + <IC k b k1
C
C
(1 C ) 0g kcetuximab
50 cetuximab
cisplatin
(11)
The TSE curve, which separates tumor growth from tumor
shrinkage, will therefore consist of all concentration pairs
C C( , )cetuximab cisplatin such that the left-hand side in Eq. (11) is equal to
zero. Solving for Ccisplatin gives
⎜ ⎟= ⎛⎝ − +
⎞
⎠ −
k
bk
I
IC b
C 1 C
C
1g
k
cisplatin
max cetuximab
50 cetuximab (12)
Insertion of the pharmacodynamic parameter estimates for the
tumor model into Eq. (12) produces the TSE curve shown in blue in
Fig. 4. The region of concentration pairs that will lead to tumor era-
dication is shown in green, whereas the region that will not eradicate
Fig. 2. Tumor volume (mm3)-time courses of observed (symbols) and model-
predicted (solid lines) data for each of the four treatment arms: (A) vehicle, (B)
cetuximab monotherapy, (C) cisplatin monotherapy, and (D) combination
therapy with cetuximab and cisplatin.
Fig. 3. Tumor growth inhibition TGI model for combination therapy with independent drug action. The model consists of a main compartment V1 and three damage
compartments, V2,V3, andV4 that cells pass through before dying. Cetuximab (A) inhibits cell proliferation with inhibitory function I C( )cetuximab , whereas cisplatin (B)
stimulates cell apoptosis with stimulatory function S C( )cisplatin . The kg and kk parameters represent the natural cell kill and death rates.
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the tumor is shown in red. The intersections with the coordinate axes
give the TSE values of 506 μg/mL and 56 ng/mL for cetuximab and
cisplatin. These values correspond to the necessary exposure for tumor
regression based on monotherapy with the respective compounds. The
curve exhibits a weak curvature compared to a reference straight line
between the TSE values (black, dashed).
The slight curvature indicates that there is only a slight advantage
from combining the two compounds with respect to tumor regression.
However, a complete assessment of the combination would also require
taking into account the toxicity of both compounds when given as
single agent as well as any toxicological interactions.
3.5. Translation of tumor static exposure to humans
Translation of the tumor model for cetuximab and cisplatin therapy
and the associated TSE curve was considered by means of allometric
scaling. The primary candidates for scaling were the rate constants kg
and kk. Scaling is generally performed based on the relative body
weight (BW) of the animals (mouse and man) with a typical value for
the exponent of − 0.25 (West et al., 2002). Hence, the following para-
meter scalings were applied:
⎜ ⎟= ⎛⎝
⎞
⎠
−
k BW
BW
kg ghuman
human
mouse
0.25
mouse
(13)
⎜ ⎟= ⎛⎝
⎞
⎠
−
k BW
BW
kk khuman
human
mouse
0.25
mouse
(14)
where typical body weights of human and mouse were assumed to
be 70 kg and 25 g, respectively.
The TSE curve in Eq. (12) depends on the rate parameters only
through their quotient, which will remain the same if the same scaling
factor is used for kg and kk. Hence, from the perspective of allometric
scaling, the TSE curve should be the same for mouse and human and
Fig. 5 can be used for predictions in humans. Note, however, that
realizations of the tumor model will look diﬀerent depending on the
allometric scaling used, but the qualitative behavior is the same (i.e.,
growing or shrinking tumor).
3.6. Conclusions from case study I
The case study taught us to analyze tumor volume data obtained
from diﬀerent combinations of two diﬀerent compounds, and how the
TSE curve could be constructed and displayed. We did simulations of
the time courses of tumor growth curves with diﬀerent dose combina-
tions of the two compounds. The resulting predictions showed the
tumor volume-time behavior when we focused on chemical compound
combinations targeting tumor shrinkage, tumor stasis or tumor growth.
The TSE curve demonstrated a weak synergistic eﬀect from combining
cetuximab and cisplatin. An allometric scaling approach indicated that
the predicted TSE curve may be the same across species.
4. Case study II: radiation and radiosensitizer
4.1. Problem formulation
This case study is based on results from a previous publication
(Cardilin et al., 2018). Radiation therapy is commonly applied in cancer
treatment for a wide range of tumors (Shaue and McBride, 2015). Ra-
diation damages the DNA of cells, e.g., through single- or double-strand
breaks, and can lead to cell death or loss of the cell's proliferative
capabilities (Eriksson and Stigbrand, 2010; Ross, 1999). The beneﬁts of
combining radiation therapy with diﬀerent doses of a radiosensitizing
agent were investigated. The goal was to develop a tumor model that
describes experimental data of radiation and radiosensitizer treatment
and to apply the model for evaluation of combinations with respect to
synergy and overall eﬃcacy using TSE curves. In addition, the trans-
lational aspects of the model were demonstrated for the human situa-
tion.
4.2. Experimental data
Eighty FaDu xenograft mouse models were used in the study. The
mice were divided into eight treatment arms with =N 10 mice in each
arm as follows: (A) vehicle, (B) radiation (2 Gy per dose), (C-E)
monotherapy with a radiosensitizing compound (10, 50, or 200mg/kg
per dose), and (F-H) combination therapy (2 Gy and 10, 50, or 200mg/
kg per dose). Mice were given daily treatments for ﬁve days. Some
tumor volume-time courses representing diﬀerent treatment arms are
Fig. 4. The Tumor Static Concentration (TSE) curve for combinations of ce-
tuximab and cisplatin plasma concentrations (blue, bold) separating regions of
tumor growth (light red) and tumor shrinkage (light green). Reference straight
line connecting the individual TSE values (black, dashed). (For interpretation of
the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 5. Representative examples of individual ﬁts for the following treatment
arms: (A) vehicle, (B) radiation therapy with 2 Gy per dose, (E) RS1 mono-
therapy with 200mg/kg per dose, and (F-H) combination therapy with 2 Gy per
dose and 10, 50, or 200mg/kg per dose of the radiosensitizer, respectively.
T. Cardilin et al. European Journal of Pharmacology 834 (2018) 327–336
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shown in Fig. 5. Further details of the study can be found in Cardilin
et al. (2018).
4.3. Pharmacodynamic model analysis
Exposure to the radiosensitizing compound was described using a
standard one-compartment model. To describe the tumor growth data,
a TGI model was modiﬁed to account for radiation therapy. The mod-
iﬁed model consists of a main compartment V1 of proliferating cancer
cells following logistic growth, and three damage compartments, V V,2 3
and V4, which cells must traverse before dying. Irradiated cells are in-
stantaneously transferred to a separate compartment where they are
allowed at most one more cell division before dying. Drug action of the
radiosensitizing agent is described as separate stimulations of both the
natural- and the radiation-induced cell deaths. The full model is shown
in Fig. 6.
The tumor model was mathematically described using the following
system of diﬀerential equations
= ⎛⎝ − ⎞⎠ − − −
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= −
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= − − −
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= + + + + +
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where kg is the growth rate, kk the kill rate, K the tumor capacity
parameter, R is the rate function for radiation, corresponding to a se-
quence of instantaneous cell transfers (mathematically described as a
series of Dirac delta distributions), and S1 is a linear stimulatory
function of the radiosensitizer given by
= +S C aC( ) 11 (16)
where a is a pharmacodynamic parameter associated with monotherapy
with the radiosensitizer. The system in Eq. (15) has the initial condi-
tions
⎜ ⎟= ⎛⎝
⎞
⎠
= = =
−
V V k
k
i U j(0) , 1, 2, 3, 4 and (0) 0, 1, 2i k
g
i
j
0
1
(17)
Finally, the fraction of lethally irradiated cells given a radiation
dose D and concurrent plasma concentration C is given by
= − + = +SF D C S C αD βD S C bC( , ) exp[ ( )( )], where ( ) 12 2 2 (18)
where α and β are the linear and quadratic radiation parameters, re-
spectively, and b is a pharmacodynamic parameter associated with
stimulation of the radiation eﬀect. Following a nonlinear-mixed eﬀects
approach, population parameter mean estimates were given by
= −k 0.50 dayg 1, = −k 0.28 dayk 1, =K 2200 mm3, =V 400 mm3,
= −α 0.08 Gy 1, = −β 0.008 Gy 2, =a 0.09 mL/µg, and =b 0.45 mL/µg.
4.4. Tumor Static Exposure (TSE) of radiation and radiosensitizer
The main compartment V1 dominates the tumor model in the same
sense as in Case study 1, i.e., if V1 is eradicated, the entire tumor will
eventually be eradicated. In this case, cell proliferation is not exclusive
to V2, but is also included in the transfer from U1 to U2. However, the
irradiated cells are only allowed to proliferate once (the resulting
daughter cells are non-proliferating) and can therefore not sustain the
tumor by themselves. Moreover, given that the treatment goal is tumor
regression and ultimately eradication, we can safely ignore the sa-
turation eﬀect that occurs for large tumor volumes. The diﬀerential
equation for V1 in Eq. (15) therefore essentially reads
= − − −dV
dt
k V S C k V SF D C RV( ) (1 ( , ))g k1 1 1 1 1 (19)
Fig. 6. Tumor model describing the radiation and radiosensitizing treatments. The vehicle model, shown in blue, consists of a main compartment V1 of proliferating
cancer cells with growth rate kg and natural kill rate kk. Before dying, cells must traverse a set of damage compartments V2, V3, and V4. Radiation induces an
instantaneous transfer of cells between V1 and U1, after which cells are allowed up to one more cell division before dying. The radiation-induced mass transfer is
shown in red. The radiosensitizer stimulates both the natural death process (shown in green, S C( )1 ) and the radiation-induced cell death (also shown in green, S C( )2 ).
The latter eﬀect is only present in individuals treated with combination therapy. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Upon irradiation at time =t 0, a fraction SF D C( , (0)) of the cells
survive. This fraction will then continue to grow according to Eq. (19)
until the time T of the next irradiation. The fraction of surviving cells,
for times between the ﬁrst and second instance of radiation, will be
given by
∫⎜ ⎟= ⎛
⎝⎜
⎞
⎠⎟
⎛
⎝
− ⎞
⎠
V t SF D C k t k S C s ds( ) , (0) exp ( ( ))g k
t
1 0 1 (20)
Hence, if =V T V( ) (0)1 1 the main compartment will be in approx-
imate stasis, and if <V T V( ) (0)1 1 the main compartment will have
shrunk. If such dosing is repeated, the main compartment will continue
to shrink and eventually be eradicated. By using Eqs. (18) and (20), it is
possible to derive an expression for the TSE curve (see Cardilin et al.,
2018 for details). The main compartment will be in approximate stasis
if
⎟⎜ ⎟⎛⎝ + −
⎞
⎠ + − −
⎞
⎠
− =−b Ck Te αD βD k k T k aTC1 1 ( ) ( 0
e
k T g k k
2
e (21)
where C̅ is the average plasma concentration of the compound, and ke is
its elimination rate according to the pharmacokinetic model. The region
of all average plasma concentrations and radiation doses that result in
tumor shrinkage will therefore consist of those for which the left-hand
side in Eq. (21) becomes negative. If we view Eq. (21) as a quadratic
equation with respect to the radiation dose D we can use standard
formulas to solve for D and ﬁnd
= − + + − −D G α G α G β k T k T k aC
G β
( ) ( ) 4 ( )( )
2 ( )
g k k
2
(22)
where D is the daily radiation dose, C denotes the average plasma
concentration of the radiosensitizing compound over the period T[0, ],
and the function G is given by
= + − −G x x
bCk Tx
e
( )
1
e
k Te (23)
Inserting the population parameter values into Eq. (22) produces
the TSE curve in Fig. 7. The curve exhibits a large curvature due to
strong synergy between the treatments. In particular, the (relatively)
large value of the interaction parameter b represents this synergy. The
shrinkage, or eradication area (green) is therefore increased sig-
niﬁcantly compared to the case =b 0 (black, dashed curve). This means
that tumor regression will be possible at much lower combination ex-
posures.
In particular, we ﬁnd the individual TSE values to be approximately
2.17 Gy for radiation and 8.26 µg/mL for the radiosensitizer, corre-
sponding to monotherapy with either treatment.
4.5. Translation of tumor static exposure to humans
An allometric scaling approach was used to translate the tumor
model and the associated TSE curve to humans (Boxenbaum, 1984;
Kang and Lee, 2011). The rate constants kg , kk, and ke, were scaled
using a standard allometric exponent b =− 0.25 (Savage et al., 2008).
Assuming body weights of 25 g and 70 kg for the mouse and man, re-
spectively, the rate constants in man were decreased to approximately
one seventh of their values in the mouse. Speciﬁcally, the rates were
scaled as
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⎞
⎠
−
k BW
BW
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human
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0.25
mouse
(24)
⎜ ⎟= ⎛⎝
⎞
⎠
−
k BW
BW
kk khuman
human
mouse
0.25
mouse
(25)
⎜ ⎟= ⎛⎝
⎞
⎠
−
k BW
BW
ke ehuman
human
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Moreover, the Dirac delta distribution, which describes the transfer
of cells during irradiation, has a unit of 1/day and was therefore scaled
in the same manner. Based on the allometrically scaled parameters, a
prediction of TSE in man can be produced. Fig. 8 (left) shows the TSE
curves for mouse (blue) and man (red), respectively. Fig. 8 (right)
shows the resulting tumor growth curves following treatment with
three diﬀerent exposure levels (A, B, and C). Similarly to the TSC curve
for cetuximab and cisplatin from case study I, the TSE values for
monotherapy with either compound are the same for mouse and man.
However, due to slower clearance in man, the corresponding TSE curve
has less curvature. This follows because slower clearance makes the
diﬀerence between peak and average plasma concentration smaller.
Although the TSE curve exhibits less curvature, lower human clearance
of the radiosensitizer suggests that less drug is needed to achieve a
plasma concentration exceeding the TSE.
4.6. Conclusions from case study II
Case study II taught us to analyze tumor volume data obtained from
diﬀerent combinations of chemical and radiation interventions, and
how the TSE curve was constructed and displayed for a relevant ad-
ministration schedule. We also extended the underlying tumor model
with a semi-mechanistic approach to show how intervention from
chemicals and radiation jointly act upon the tissue growth/kill. The
calibrated model showed good predictive capabilities for all treatment
arms. The TSE curve associated with radiation and radiosensitizer
combinations demonstrated a strong synergistic eﬀect from combina-
tion therapy treatment. An allometric scaling approach showed diﬀer-
ences in TSE across species due to diﬀerences in drug clearance.
5. Discussion
This paper was focused on two questions: Can quantitative techni-
ques provide a better understanding of tumor volume data when
combinations of chemicals and radiation are used? and What
Fig. 7. The Tumor Static Exposure (TSE) curve as a function of radiation dose
and radiosenzitizer concentration. The set of all concentration-dose pairs that
yield tumor shrinkage upon daily administration is shown in green.
Concentration pairs outside this region lead to tumor growth and are shown in
red. The TSE curve is shown in blue and can be compared to the case with no
synergy =b( 0), shown in black (dashed). The TSE curve has signiﬁcant cur-
vature due to a pronounced synergistic eﬀect between the treatments. (For
interpretation of the references to color in this ﬁgure legend, the reader is re-
ferred to the web version of this article.)
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translational potential does such an approach have? We shall discuss
these two questions in the rest of this section.
5.1. Quantitative tumor models
Quantitative techniques play an important role in modern phar-
macology in order to improve our understanding of dose-exposure-re-
sponse relationships (Standing, 2017; Gabrielsson and Green, 2009). In
particular, pharmacokinetic and pharmacodynamic models have
proven useful in describing tumor growth after administration of an-
ticancer agents, displaying good predictive capabilities (Li et al., 2013;
Zhu et al., 2015). In the case of combination therapy with multiple
compounds, quantitative models have also been useful to identify and
quantify potential drug synergies (Choo et al., 2013; Frances et al.,
2011). We presented two models of combination therapies in oncology
(Cardilin et al., 2017, 2018) and two case studies that involved com-
binations of two agents. Our results indicate that TSE can be used to
assess and quantify synergy between diﬀerent compounds, and that a
quantitative approach provides a better understanding of tumor growth
and how to intervene with combinations of drugs and/or therapies.
The ﬁrst model, used to describe cetuximab and cisplatin, shares
many similarities with previous tumor growth models (e.g., Goteti et al.,
2010; Rocchetti et al., 2013) but there are a few important diﬀerences.
Firstly, our model incorporates a natural rate of cell death, meaning
that even in the absence of treatment, some cells will be in the process
of dying. This captures some of the heterogeneity of cancer cells and
consequently provides a somewhat more biologically reasonable model.
The inclusion of a natural death rate also meant that the initial dis-
tribution of cancer cells had to be revised (Cardilin et al., 2017).
The second model, used to describe radiation therapy combined
with radiosensitizing treatment, has several novel aspects. One the one
hand, the model can be seen as a generalization of the ﬁrst model in
that it includes the common structure of proliferating cells and a chain
of transit compartments representing increasingly damaged cells
(Simeoni et al., 2004). On the other hand, since we wanted to describe
the eﬀects of radiation therapy, we took some inspiration from the
linear-quadratic theory of radiobiology (Brenner, 2008; Brenner et al.,
1998). By combining these two perspectives, we arrived at a model
that, while novel, is still founded on practical and empirical evidence.
This was further consolidated when the model was used to predict the
outcome following a prolonged administration schedule (Cardilin et al.,
2018).
For both models we introduce the concept of TSE for combinations
of anticancer agents. The TSE concept is a generalization of the Tumor
Static Concentration value discussed by Jumbe et al. (2010) among
others. TSE provides insight about drug eﬃcacy and the in vivo sensi-
tivity of tumor cells. In particular, TSE identiﬁes drug exposure that is
suﬃcient for tumor regression for monotherapies as well as combina-
tion therapies involving two or more compounds. Most importantly,
TSE provides guidance for clinical dose regimen selection, where dosing
interval troughs should exceed these concentrations for the eﬀective
tumor kill rate to exceed tumor growth rates for net antitumor activity.
In other words, a quantitative approach provides a better under-
standing of tumor growth and how to intervene with combinations of
drugs and/or therapies.
The two case studies we presented both involve combinations of two
agents. The resulting TSE curves separate exposure pairs yielding tumor
regression (green regions) from those that yield tumor growth (red
regions). The curvature of the TSE curve is associated with the strength
of synergy between the treatments. In case study I (cetuximab and
cisplatin) the associated TSE curve (Fig. 4) indicated a weak synergistic
eﬀect, whereas in case study II (radiation and a radiosensitizer), the TSE
curve (Fig. 7) indicated a strong synergy. We conclude that TSE can also
be used to assess and quantify synergy between diﬀerent compounds.
5.2. Translational potential
Since mechanism-based pharmacodynamic tumor models are based
on measured exposure to drugs and complete volume-time curves, in
contrast to the isobologram used for diﬀerent dose combinations aiming
at equal eﬃcacies (Tallarida, 2006), the proposed concepts have a
much stronger potential for translation of doses to systemic exposures,
and observations in animal species to human plasma target con-
centrations. In an attempt to translate TSE to humans, we used an al-
lometric scaling approach (Boxenbaum, 1982). We described how
physiological or system parameters (i.e., kg and kk) and drug rate
parameters (ke) may be allometrically scalable across diﬀerent strains
and species, including prediction of human doses. This approach is
consistent with what has been tried for other tumor models (Herman
et al., 2011; Lindauer et al., 2017). However, our approach relies on an
assumption that drug-related parameters, e.g., EC50, are approximately
the same across species. This is consistent with what others have
Fig. 8. (left) Predicted TSE curves for mouse (blue) and man (red), and (right) simulated tumor growth in mouse (blue) and man (red) following average exposures of
A: (0.25 Gy, 1 µg/mL), B: (0.5Gy, 2 µg/mL), and C: (0.75Gy, 3 µg/mL). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
web version of this article.)
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studied regarding allometric scaling of pharmacodynamic parameters
(e.g., Lui et al., 2016; Mager et al., 2009; Zuideveld et al., 2007). In
particular, Mager et al. (2009) note that physiological turnover rates
are often allometrically scalable across species, whereas parameters
related to capacity and sensitivity tend to be similar. For the second
model, we chose to scale the fraction lethally irradiated cells. One
reason for this was reasonability – had we chosen not to scale this
fraction, the necessary radiation doses tumor shrinkage would have
been much lower than what is reasonable. Another argument is that the
fraction of lethally irradiated tumor cells is formally described by a
Dirac delta distribution with unit −days 1 and is therefore in a sense si-
milar to a rate parameter. It is worth keeping in mind that allometry is
not perfect and has not always agreed with empirical observations, and
alternative approaches have been discussed, see for instance Agutter
and Tuszynski (2011). When we applied allometric scaling to the model
in case study I, the TSE curve remained the same across species. In
contrast, when we applied allometric scaling to case study II, diﬀer-
ences in drug clearance resulted in diﬀerent curvatures of the TSE
curves.
Finally, we believe that TSE is also applicable to diﬀerent cell-lines
since both growth (kg) and natural cell kill (kk) appear as intrinsic
properties of the models. The models are not limited to a net growth
expression, but instead consider separate growth and (natural) death
rates. Moreover, the models encompass the utility of multiple drug (or
radiation) interventions in their basic structure.
6. Conclusions
Our analysis focused speciﬁcally on deriving necessary mathema-
tical tools and then implementing graphical ways to visualize ad-
ditivity, synergy or antagonism based on exposure metrics. A quanti-
tative mathematical/analytical approach strongly demonstrated its
feasibility in pharmacology. The TSE analysis can easily be im-
plemented in the drug discovery process and used as an independent
approach to select or de-select compounds. The TSE concept has a
unique potential for ranking of compounds and support the compound
selection process in drug discovery, since it embodies model-based
metrics of both drug (EC50) and target properties (kg and kk), where all
experimental data (tumor volume time courses) are taken into account.
The graphical TSE method is a valuable way to communicate compli-
cated processes to non-quantitative experts. The translational potential
was shown in two case studies.
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Appendix A
This appendix provides an introduction to the concepts of Tumor Static Concentration (TSC) and more generally, Tumor Static Exposure (TSE)
from a mathematical perspective.
TSE for monotherapy with an anti-cancer agent
We consider a general tumor growth inhibition (TGI) model with n cell compartments with volumes …V V, , n1 and exposure to an anti-cancer agent
A
= =dV
dt
f V E V V( ; ), (0) 0 (A1)
where = …V V V( , , )n1 is the vector of compartment volumes, = …f f f( , , )n1 the growth rate of each compartment, = …V V V( , , )n0 10 0 is the vector of the
initial volumes of each compartment at time =t 0, and E the exposure to compound A. Typically, we will have =E C , i.e., the (plasma) con-
centration of the compound. However, in the case of radiation therapy for example, Dose-Response-Time modelling will need to be considered.
Hence, =E D, the (radiation) dose. Theoretically, there could also be other ways of expressing the exposure to certain anti-cancer agents.
We shall ﬁrst consider the case where E is constant and then move on to the case where E varies depending on the administration schedule. We
would like to ﬁnd all exposure levels of A that result in tumor eradication, i.e., we are interested in the set
= ⎧⎨⎩
> = ∀ ≥ ⎫⎬⎭→∞
S E V t C V0 : lim ( ; ) 0, 0
t
0
(A2)
If we further assume that anti-tumor activity is monotonically increasing with exposure, we are particularly interested in the smallest exposure
that leads to tumor eradication, which we deﬁne as the tumor static exposure (TSE) value of compound A.
= >TSE SinfA E 0 (A3)
The TSE value will then have the property that for any >E TSEA the tumor will be eradicated following maintained exposure. When =E C we
shall sometimes also refer to the TSE value as the tumor static concentration (TSC). An illustration of the TSE value is given in Fig. 1a. The basic
guideline would then be the following: choose an administration schedule for compound A such that the exposure level is kept aboveTSEA. This will
ensure tumor regression and eventual eradication.
TSE for combination therapy with two anti-cancer agents
For combination therapy with two compounds, denoted A1 and A2, we consider the same tumor model (Eq. (A1)) with exposure vector
=E E E( , )1 2 , where E1 represents the exposure to compound A1 and E2 represents the exposure to compound A2. Analogously to the case with a single
compound, we deﬁne the set S of simultaneous exposures E that yield tumor eradication
= ⎧⎨⎩
> = ∀ ≥ ⎫⎬⎭→∞
S E E V t E V( , ) 0 : lim ( ; ) 0, 0
t
1 2
0
(A4)
The set S is a region in the positive exposure plane. We deﬁne the TSE curve to be the boundary of this set
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= ∂TSE SA A( , )1 2 (A5)
The TSE curve divides the ﬁrst quadrant of the exposure plane into two regions: one which will lead to tumor eradication, and another in which
the tumor will persist. An illustration of a TSE curve is given in Fig. 1b. The points where the TSE curve intersects the coordinate axes will be the TSE
values of the respective compounds. The general guideline remains the same: choose administration schedules for A1 and A2 such that the exposure
pair E is kept above the TSE curve, i.e., in the green region in Fig. 1b.
TSE for combination therapy with three or more anti-cancer agents
The TSE concept can be generalized to an arbitrary number of anti-cancer compounds, …A A, , m1 with an m-dimensional vector of exposures
= …E E E( , , )m1 . We deﬁne the set S
= ⎧⎨⎩
> = ∀ ≥ ⎫⎬⎭→∞
S E V t E V0 : lim ( ; ) 0, 0
t
0
(A6)
and the TSE set as its boundary
= ∂…TSE SA A( , , )m1 (A7)
In particular, for three compounds, the TSE set will be a surface in three-dimensional exposure space. An illustration of a TSE surface is given in
Fig. 1c.
TSE for ﬁxed administration schedules
An important generalization is to allow E to vary according to a given administration schedule. We shall consider administration schedules that
are repeated. The simplest example being daily bolus dosing, but also, e.g., biweekly dosing belongs to this category. The primary case is =E D, but
another possibility would be to use the resulting average plasma concentration C when applicable. We can once more consider the tumor model in
Eq. (A1), where we think of the administration schedule as being incorporated into f . We can now pose questions such as this: For which values of E ,
repeated according to the given administration, will the tumor eventually be eradicated? We then deﬁne the set S and the TSE value as in Eq. (A3).
This construction can be performed for an arbitrary number of compounds in the same way as presented above.
Further generalizations of the TSE concept are possible. In particular, it is possible to consider diﬀerent administration schedules. This means that
E will be a time-varying function belonging to some vector space. The corresponding shrinkage set S will then consist of all, say L2, functions E for
which the tumor will be eradicated. Consequently, S will be a subset of an inﬁnite-dimensional vector space of functions. This is the same perspective
that is used in Optimal Control theory, which has been applied to diﬀerent tumor models in order to optimize the treatment eﬀect (Schättler and
Ledzewics, 2015; Sbeity and Younes, 2015) However, because the optimal administration schedule is often diﬃcult to determine, one has to settle for
describing certain properties that the optimal solution possesses. Moreover, the solutions can be sensitive with respect to perturbations in the
parameter estimates (Sbeity and Younes, 2015).
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